References
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Eng J Med. 2017;377:644–657.
- The Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314:52–60.
- The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
- Saydah S, Eberhardt M, Loria C, et al. Age and the burden of death attributable to diabetes in the United States. Amer J Epidemiol. 2002;156:714–719.
- UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
- Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
- Anderson S, Marrs J. Antihyperglycemic medications and cardiovascular risk reduction. Eur Endocrinol. 2017;13(2):86–90.
- Mahaffey K, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary precvention of cardiovascular events: results form the CANVAS program (canagliflozin cardiovascular assessment study). Circulation. 2017 Nov 13.
- Kosiborod M, Cavender M, Fu A, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017 May 18;136:249–259.
- Toulis K, Willis B, Marshall T, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvement network database. J Clin Endocrinol Metab. 2017;102(5):1719–1725.
- Wu J, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411–419.
- Guthrie R. Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes. Postgrad Med. 2016;128(4):335–337.
- Abdul-Ghani M, DeFronzo R, Del Prato S, et al. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? Diabetes Care. 2017;40:813–820.
- Verma S, Garg A, Yan A, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial. Diabetes Care. 2016;39:e212–e213.
- Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN trials. Diabetes Care. 2017;40:821–831.
- Januzzi J, Butler J, Jarolim P, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. JACC. 2017;70(6):704–712.
- Pharmacovigilance Risk Assessment Committee (PRAC). European Medical Agency. SGLT-2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. Issue by the Agency; 2017 Feb 9. EMA/PRAC/637349/2016.
- Fraxiga prescribing information. Revised edition. 2017 Oct. Princeton, NJ: Bristol-Myers Squibb Co.; Wilmington, DE: Astra Zeneca Pharmaceuticals LP.